Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026

{
  "signal_id": "cdacc373-eeb0-750d-72b1-1d7d4a9d2239",
  "signal_type": "news",
  "signal_subtype": "has_earnings",
  "detected_at": "2026-09-24T20:05:00+00:00",
  "company": {
    "name": "Regeneron",
    "domain": "regeneron.com"
  },
  "data": {
    "url": "https://www.globenewswire.com/news-release/2026/09/24/3368733/0/en/regeneron-to-report-third-quarter-2026-financial-and-operating-results-and-host-conference-call-and-webcast-on-october-30-2026.html",
    "title": "Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026",
    "excerpt": "TARRYTOWN, N.Y., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that it will report its third quarter 2026 financial and operating results on Friday, October 30, 2026, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the ‘Investors and Media’ page of Regeneron’s website at https://investor.regeneron.com . To participate via telephone, please register in advance at this link . Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay and transcript of the conference call and webcast will be archived on the Company’s website for at least 30 days. About Regeneron Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our...",
    "summary": "Regeneron Pharmaceuticals will report its third quarter 2026 financial and operating results on October 30, 2026.",
    "location": "Tarrytown, N.Y.",
    "planning": false,
    "image_url": "https://ml.globenewswire.com/Resource/Download/add5ebc7-88c9-49dc-8834-abbb07c622d1",
    "confidence": 0.9,
    "published_at": "2026-09-24T20:05:00Z",
    "location_data": [
      {
        "city": "Tarrytown",
        "state": "New York",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-10-30",
    "article_sentence": "Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that it will report its third quarter 2026 financial and operating results on Friday, October 30, 2026, before the U.S. financial markets open."
  }
}

curl https://signals.autobound.ai/v1/signals/cdacc373-eeb0-750d-72b1-1d7d4a9d2239 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"regeneron.com","limit":20}'